<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688451</url>
  </required_header>
  <id_info>
    <org_study_id>UCCI-HEM-17-01</org_study_id>
    <nct_id>NCT03688451</nct_id>
  </id_info>
  <brief_title>Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma</brief_title>
  <official_title>A Pilot Study to Access the Feasibility and Safety of Intrathecal Rituximab Added to Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20 Positive Non Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tahir Latif</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn if giving rituximab, the study drug, right
      into the spinal canal along with chemotherapy drugs like methotrexate is possible and safe.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential dose cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to deliver greater than 80% of planned doses</measure>
    <time_frame>28 months</time_frame>
    <description>Percentage of planned doses administered for planned accrual</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Related Grade 3 or higher non-hematological toxicity</measure>
    <time_frame>28 months</time_frame>
    <description>Number of related grade 3 or higher non-hematological toxicities</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Intrathecal rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: 10 mg dose, day 1 chemotherapy cycles 2-5 Cohort 2: 20 mg dose, day 1 chemotherapy cycles 2-5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Intrathecal administration over 3-5 minutes</description>
    <arm_group_label>Intrathecal rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CD20 positive diffuse large b-cell lymphoma undergoing treatment with systemic
             rituximab in combination with CHOP, CHOEP, or EPOCH and deemed high risk of CNS
             relapse and eligible for central nervous system prophylaxis with intrathecal therapy.

        Exclusion Criteria:

          -  Primary central nervous system lymphoma or established secondary central nervous
             system disease.

          -  History of spinal surgery and/or ineligible for intrathecal injections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tahir Latif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UC Cancer Institute Clinical Trials Office</last_name>
    <phone>513-584-7698</phone>
    <email>cancer@uchealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Health</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UC Cancer Institute Clinical Trials Office</last_name>
      <phone>513-584-7698</phone>
      <email>cancer@uchealth.com</email>
    </contact>
    <investigator>
      <last_name>Tahir Latif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Tahir Latif</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

